FLGT * Stock Overview
Provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Fulgent Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$330.00 |
| 52 Week High | US$459.00 |
| 52 Week Low | US$315.00 |
| Beta | 1.54 |
| 1 Month Change | -6.52% |
| 3 Month Change | -13.16% |
| 1 Year Change | n/a |
| 3 Year Change | -72.78% |
| 5 Year Change | n/a |
| Change since IPO | -65.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| FLGT * | MX Healthcare | MX Market | |
|---|---|---|---|
| 7D | 4.8% | 1.3% | -0.7% |
| 1Y | n/a | -13.7% | -9.7% |
Return vs Industry: Insufficient data to determine how FLGT * performed against the MX Healthcare industry.
Return vs Market: Insufficient data to determine how FLGT * performed against the MX Market.
Price Volatility
| FLGT * volatility | |
|---|---|
| FLGT * Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in MX Market | 7.4% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: FLGT *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine FLGT *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,313 | Ming Hsieh | www.fulgentgenetics.com |
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
Fulgent Genetics, Inc. Fundamentals Summary
| FLGT * fundamental statistics | |
|---|---|
| Market cap | Mex$10.59b |
| Earnings (TTM) | -Mex$850.97m |
| Revenue (TTM) | Mex$5.65b |
1.9x
P/S Ratio-12.4x
P/E RatioIs FLGT * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLGT * income statement (TTM) | |
|---|---|
| Revenue | US$283.47m |
| Cost of Revenue | US$176.26m |
| Gross Profit | US$107.22m |
| Other Expenses | US$149.92m |
| Earnings | -US$42.71m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.39 |
| Gross Margin | 37.82% |
| Net Profit Margin | -15.07% |
| Debt/Equity Ratio | 0.3% |
How did FLGT * perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/15 18:00 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fulgent Genetics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Karen Koski | BTIG |
| Andrew Cooper | CGS International |
| Erin Wilson Wright | Credit Suisse |